Robert L. Kormos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert L. Kormos has a total of 246 co-authors. Here are the top co-authors by number of shared publications:
- Francis D. Pagani
Department of Cardiac Surgery, University of Michigan Medical School, Ann Arbor, Michigan
8 shared publications - Keith D. Aaronson
Division of Cardiovascular Medicine, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, Michigan
7 shared publications - Carol E. Chenoweth
Division of Infectious Diseases, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor. (S.Z., C.E.C., P.N.M.).
5 shared publications - Donald S. Likosky
Department of Cardiac Surgery, University of Michigan Medical School, Ann Arbor, Michigan
5 shared publications - John M. Hollingsworth
Dow Division of Health Services Research, Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan
5 shared publications - Lourdes Cabrera
Department of Cardiac Surgery, Michigan Medicine, University of Michigan, Ann Arbor. (S.S., L.C., H.H., S.C., F.D.P., D.S.L.).
5 shared publications
Latest Publications
- 27 August 2026
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (10) , 1781-1794
From Rescue to Interception: The PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer) Framework for Advanced Heart Failure
- 27 August 2026
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (10) , 1781-1794
From Rescue to Interception: The PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer) Framework for Advanced Heart Failure
- Open Access
- 4 November 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e044373
Contemporary Practice Patterns of Vasoactive Use in Cardiogenic Shock in the American Heart Association Cardiogenic Shock Registry
Background: Vasoactives are the predominant first line of therapy for management of cardiogenic shock (CS). Contemporary practice patterns regarding vasoactive agent selection in CS have not been well characterized. Methods: The American Heart Association (AHA) CS Registry captures consecutive CS admissions across participating hospitals in the United States. Admissions treated with vasoactive agents within 6 hours of CS onset were included. Agents were categorized as inopressors (norepinephrine, epinephrine, dopamine), inodilators (dobutamine, milrinone), and pure vasopressors (vasopressin, phenylephrine). Results: From 2022 to 2024, among 6847 CS admissions across 84 sites, 3387 (49.5%) were treated with a single vasoactive agent and 3460 (50.5%) were treated with ≥2 agents. Inopressors were used most commonly (73.7% of CS cases), with inodilators and pure vasopressors used in 48.3% and 27.5% of cases respectively. Norepinephrine was used most frequently (64.7%), followed by dobutamine (31.6%) and epinephrine (28.9%). Pure vasopressor use consisted primarily of vasopressin (83.5% of use). Use patterns differed by CS etiology with greater inopressor use in acute myocardial infarction‐CS and greater inodilator use in acute‐on‐chronic heart failure‐CS. Use of inopressors and pure vasopressors was greater and inodilator use lower in those with cardiac arrest, supported by mechanical circulatory support, or at higher Society of Cardiovascular Angiography and Interventions shock stage. Conclusions: In a broad population with CS in contemporary practice, inopressors are the most commonly used vasoactive category, with norepinephrine being the most frequently used agent. Several factors including CS etiology and severity are associated with differential practice patterns for vasoactive selection. These data depict the contemporary landscape and may help inform future evidence generation around optimal vasoactive selection for patients with CS.
- 4 November 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e044373
Open AccessContemporary Practice Patterns of Vasoactive Use in Cardiogenic Shock in the American Heart Association Cardiogenic Shock Registry
Background: Vasoactives are the predominant first line of therapy for management of cardiogenic shock (CS). Contemporary practice patterns regarding vasoactive agent selection in CS have not been well characterized. Methods: The American Heart Association (AHA) CS Registry captures consecutive CS admissions across participating hospitals in the United States. Admissions treated with vasoactive agents within 6 hours of CS onset were included. Agents were categorized as inopressors (norepinephrine, epinephrine, dopamine), inodilators (dobutamine, milrinone), and pure vasopressors (vasopressin, phenylephrine). Results: From 2022 to 2024, among 6847 CS admissions across 84 sites, 3387 (49.5%) were treated with a single vasoactive agent and 3460 (50.5%) were treated with ≥2 agents. Inopressors were used most commonly (73.7% of CS cases), with inodilators and pure vasopressors used in 48.3% and 27.5% of cases respectively. Norepinephrine was used most frequently (64.7%), followed by dobutamine (31.6%) and epinephrine (28.9%). Pure vasopressor use consisted primarily of vasopressin (83.5% of use). Use patterns differed by CS etiology with greater inopressor use in acute myocardial infarction‐CS and greater inodilator use in acute‐on‐chronic heart failure‐CS. Use of inopressors and pure vasopressors was greater and inodilator use lower in those with cardiac arrest, supported by mechanical circulatory support, or at higher Society of Cardiovascular Angiography and Interventions shock stage. Conclusions: In a broad population with CS in contemporary practice, inopressors are the most commonly used vasoactive category, with norepinephrine being the most frequently used agent. Several factors including CS etiology and severity are associated with differential practice patterns for vasoactive selection. These data depict the contemporary landscape and may help inform future evidence generation around optimal vasoactive selection for patients with CS.
- Open Access
- 28 July 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (1) , 103-115
Heterogeneity in HeartMate 3 implanting center infection management reveals opportunities for quality improvement and best practice initiatives during left ventricular assist device support
- 28 July 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (1) , 103-115
Open AccessHeterogeneity in HeartMate 3 implanting center infection management reveals opportunities for quality improvement and best practice initiatives during left ventricular assist device support
- 12 March 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (7) , 1172-1180
The effect of bend relief perforations upon extrinsic graft obstruction risk – a histological analysis
- 12 March 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (7) , 1172-1180
The effect of bend relief perforations upon extrinsic graft obstruction risk – a histological analysis
- 1 July 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 17 (7) , e010637
American Heart Association Cardiogenic Shock Registry: Design and Implementation
BACKGROUND: Cardiogenic shock is a morbid complication of heart disease that claims the lives of more than 1 in 3 patients presenting with this syndrome. Supporting a unique collaboration across clinical specialties, federal regulators, payors, and industry, the American Heart Association volunteers and staff have launched a quality improvement registry to better understand the clinical manifestations of shock phenotypes, and to benchmark the management patterns, and outcomes of patients presenting with cardiogenic shock to hospitals across the United States. METHODS: Participating hospitals will enroll consecutive hospitalized patients with cardiogenic shock, regardless of etiology or severity. Data are collected through individual reviews of medical records of sequential adult patients with cardiogenic shock. The electronic case record form was collaboratively designed with a core minimum data structure and aligned with Shock Academic Research Consortium definitions. This registry will allow participating health systems to evaluate patient-level data including diagnostic approaches, therapeutics, use of advanced monitoring and circulatory support, processes of care, complications, and in-hospital survival. Participating sites can leverage these data for onsite monitoring of outcomes and benchmarking versus other institutions. The registry was concomitantly designed to provide a high-quality longitudinal research infrastructure for pragmatic randomized trials as well as translational, clinical, and implementation research. An aggregate deidentified data set will be made available to the research community on the American Heart Association’s Precision Medicine Platform. On March 31, 2022, the American Heart Association Cardiogenic Shock Registry received its first clinical records. At the time of this submission, 100 centers are participating. CONCLUSIONS: The American Heart Association Cardiogenic Shock Registry will serve as a resource using consistent data structure and definitions for the medical and research community to accelerate scientific advancement through shared learning and research resulting in improved quality of care and outcomes of shock patients.
- 1 July 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 17 (7) , e010637
American Heart Association Cardiogenic Shock Registry: Design and Implementation
BACKGROUND: Cardiogenic shock is a morbid complication of heart disease that claims the lives of more than 1 in 3 patients presenting with this syndrome. Supporting a unique collaboration across clinical specialties, federal regulators, payors, and industry, the American Heart Association volunteers and staff have launched a quality improvement registry to better understand the clinical manifestations of shock phenotypes, and to benchmark the management patterns, and outcomes of patients presenting with cardiogenic shock to hospitals across the United States. METHODS: Participating hospitals will enroll consecutive hospitalized patients with cardiogenic shock, regardless of etiology or severity. Data are collected through individual reviews of medical records of sequential adult patients with cardiogenic shock. The electronic case record form was collaboratively designed with a core minimum data structure and aligned with Shock Academic Research Consortium definitions. This registry will allow participating health systems to evaluate patient-level data including diagnostic approaches, therapeutics, use of advanced monitoring and circulatory support, processes of care, complications, and in-hospital survival. Participating sites can leverage these data for onsite monitoring of outcomes and benchmarking versus other institutions. The registry was concomitantly designed to provide a high-quality longitudinal research infrastructure for pragmatic randomized trials as well as translational, clinical, and implementation research. An aggregate deidentified data set will be made available to the research community on the American Heart Association’s Precision Medicine Platform. On March 31, 2022, the American Heart Association Cardiogenic Shock Registry received its first clinical records. At the time of this submission, 100 centers are participating. CONCLUSIONS: The American Heart Association Cardiogenic Shock Registry will serve as a resource using consistent data structure and definitions for the medical and research community to accelerate scientific advancement through shared learning and research resulting in improved quality of care and outcomes of shock patients.
- Top Cited Papers
- 3 October 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (14) , 1113-1126
Standardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the Shock Academic Research Consortium (SHARC)
The Shock Academic Research Consortium is a multi-stakeholder group, including representatives from the US Food and Drug Administration and other government agencies, industry, and payers, convened to develop pragmatic consensus definitions useful for the evaluation of clinical trials enrolling patients with cardiogenic shock, including trials evaluating mechanical circulatory support devices. Several in-person and virtual meetings were convened between 2020 and 2022 to discuss the need for developing the standardized definitions required for evaluation of mechanical circulatory support devices in clinical trials for cardiogenic shock patients. The expert panel identified key concepts and topics by performing literature reviews, including previous clinical trials, while recognizing current challenges and the need to advance evidence-based practice and statistical analysis to support future clinical trials. For each category, a lead (primary) author was assigned to perform a literature search and draft a proposed definition, which was presented to the subgroup. These definitions were further modified after feedback from the expert panel meetings until a consensus was reached. This manuscript summarizes the expert panel recommendations focused on outcome definitions, including efficacy and safety.
- 3 October 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (14) , 1113-1126
Top Cited PapersStandardized Definitions for Cardiogenic Shock Research and Mechanical Circulatory Support Devices: Scientific Expert Panel From the Shock Academic Research Consortium (SHARC)
The Shock Academic Research Consortium is a multi-stakeholder group, including representatives from the US Food and Drug Administration and other government agencies, industry, and payers, convened to develop pragmatic consensus definitions useful for the evaluation of clinical trials enrolling patients with cardiogenic shock, including trials evaluating mechanical circulatory support devices. Several in-person and virtual meetings were convened between 2020 and 2022 to discuss the need for developing the standardized definitions required for evaluation of mechanical circulatory support devices in clinical trials for cardiogenic shock patients. The expert panel identified key concepts and topics by performing literature reviews, including previous clinical trials, while recognizing current challenges and the need to advance evidence-based practice and statistical analysis to support future clinical trials. For each category, a lead (primary) author was assigned to perform a literature search and draft a proposed definition, which was presented to the subgroup. These definitions were further modified after feedback from the expert panel meetings until a consensus was reached. This manuscript summarizes the expert panel recommendations focused on outcome definitions, including efficacy and safety.
- Open Access
- 23 June 2022
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (6) , e39663
Correction: Understanding and Addressing Variation in Health Care–Associated Infections After Durable Ventricular Assist Device Therapy: Protocol for a Mixed Methods Study
[This corrects the article DOI: 10.2196/14701.].
- 23 June 2022
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 11 (6) , e39663
Open AccessCorrection: Understanding and Addressing Variation in Health Care–Associated Infections After Durable Ventricular Assist Device Therapy: Protocol for a Mixed Methods Study
[This corrects the article DOI: 10.2196/14701.].
- Open Access
- 17 May 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Correction: Understanding and Addressing Variation in Health Care–Associated Infections After Durable Ventricular Assist Device Therapy: Protocol for a Mixed Methods Study (Preprint)
UNSTRUCTURED This is a corrigendum of original article ms# 14701.
- 17 May 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessCorrection: Understanding and Addressing Variation in Health Care–Associated Infections After Durable Ventricular Assist Device Therapy: Protocol for a Mixed Methods Study (Preprint)
UNSTRUCTURED This is a corrigendum of original article ms# 14701.
- 28 September 2021
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (3) , 394-401
Primary Graft Dysfunction in Heart Transplant Recipients—Risk Factors and Longitudinal Outcomes
Before the 33rd Annual International Society for Heart and Lung Transplantation conference, there was significant intercenter variability in definitions of primary graft dysfunction (PGD). The incidence, risk factors, and outcomes of consensus-defined PGD warrant further investigation. We retrospectively examined 448 adult cardiac transplant recipients at our institution from 2005 to 2017. Patient and procedural characteristics were compared between PGD cases and controls. Multivariable logistic regression was used to model PGD and immediate postoperative high-inotrope requirement for hypothesized risk factors. Patients were followed for a mean 5.3 years to determine longitudinal mortality. The incidence of PGD was 16.5%. No significant differences were found with respect to age, sex, race, body mass index, predicted heart mass mismatch, pretransplant amiodarone therapy, or pretransplant mechanical circulatory support (MCS) between recipients with PGD versus no PGD. Each 10 minute increase in ischemic time was associated with 5% greater odds of PGD (OR = 1.05 [95% CI, 1.00–1.10]; p = 0.049). Pretransplant MCS, predicted heart mass mismatch ≥30%, and pretransplant amiodarone therapy were associated with high-immediate postoperative inotropic requirement. The 30 day, 1 year, and 5 year mortality for patients with PGD were 28.4%, 38.0%, and 45.8%, respectively, compared with 1.9%, 7.1%, and 21.5% for those without PGD (log-rank, p < 0.0001). PGD heralded high 30 day, 1 year, and 5 year mortality. Pretransplant MCS, predicted heart mass mismatch, and amiodarone exposure were associated with high-inotrope requirement, while prolonged ischemic time and multiple perioperative transfusions were associated with consensus-defined PGD, which may have important clinical implications under the revised United Network for Organ Sharing allocation system.
- 28 September 2021
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (3) , 394-401
Primary Graft Dysfunction in Heart Transplant Recipients—Risk Factors and Longitudinal Outcomes
Before the 33rd Annual International Society for Heart and Lung Transplantation conference, there was significant intercenter variability in definitions of primary graft dysfunction (PGD). The incidence, risk factors, and outcomes of consensus-defined PGD warrant further investigation. We retrospectively examined 448 adult cardiac transplant recipients at our institution from 2005 to 2017. Patient and procedural characteristics were compared between PGD cases and controls. Multivariable logistic regression was used to model PGD and immediate postoperative high-inotrope requirement for hypothesized risk factors. Patients were followed for a mean 5.3 years to determine longitudinal mortality. The incidence of PGD was 16.5%. No significant differences were found with respect to age, sex, race, body mass index, predicted heart mass mismatch, pretransplant amiodarone therapy, or pretransplant mechanical circulatory support (MCS) between recipients with PGD versus no PGD. Each 10 minute increase in ischemic time was associated with 5% greater odds of PGD (OR = 1.05 [95% CI, 1.00–1.10]; p = 0.049). Pretransplant MCS, predicted heart mass mismatch ≥30%, and pretransplant amiodarone therapy were associated with high-immediate postoperative inotropic requirement. The 30 day, 1 year, and 5 year mortality for patients with PGD were 28.4%, 38.0%, and 45.8%, respectively, compared with 1.9%, 7.1%, and 21.5% for those without PGD (log-rank, p < 0.0001). PGD heralded high 30 day, 1 year, and 5 year mortality. Pretransplant MCS, predicted heart mass mismatch, and amiodarone exposure were associated with high-inotrope requirement, while prolonged ischemic time and multiple perioperative transfusions were associated with consensus-defined PGD, which may have important clinical implications under the revised United Network for Organ Sharing allocation system.
- 1 February 2021
- Published by Elsevier in Journal of Tissue Viability
- Vol. 30 (1) , 9-15
A comparison of air-cell and gel surgical table pads and an evaluation of the influence of pressure distribution and other factors on pressure injury prevention
- 1 February 2021
- Published by Elsevier in Journal of Tissue Viability
- Vol. 30 (1) , 9-15
A comparison of air-cell and gel surgical table pads and an evaluation of the influence of pressure distribution and other factors on pressure injury prevention